Role of 99mTc-glucoheptonic acid brain single photon emission computed tomography in differentiation of recurrent brain tumour and post-radiation gliosis

Australasian Radiology

Volumn 48, Issue 3, 2004, Pages 296-301

  Barai, S ^a   Bandopadhayaya, G P ^a   Julka, P K ^a   Naik, K K ^a   Haloi, A K ^a   Kumar, R ^a   Seith, A ^a   Malhotra, A ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Fanbeam collimator; Glucoheptonate; Glucoheptonate index; Post radiation gliosis; SPECT

Indexed keywords

GLUCEPTATE TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; SUGAR ACID; TECHNETIUM COMPLEX; TECHNETIUM TC 99M GLUCEPTATE;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; FOLLOW UP; GLIOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DETECTION; RADIATION NECROSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGED; BRAIN; BRAIN TUMOR; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; RADIATION EXPOSURE; RADIOTHERAPY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLIOSIS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RADIOTHERAPY; SENSITIVITY AND SPECIFICITY; SUGAR ACIDS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 7044223300     PISSN: 00048461     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0004-8461.2004.01310.x     Document Type: Article

References (24)

1. Kaplan WD, Takvorian T, Morris JH, Rumbaugh CL, Conndly BT, Atkins HL. Thallium-201 brain tumour imaging. A comparative study with pathological correlation. J Nucl Med 1987; 28: 47-52.
2. Oriuchi N, Tamura M, Shibazaki T, Ohye C, Watanabe N. Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histological grade, prognosis, and proliferative activities. J Nucl Med 1993; 34: 2089-90.
3. Yoshii Y, Satou M, Yamamoto T et al. The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumours in man and their response to treatment. Eur J Nucl Med 1993; 20: 39-45.
4. Atkins HL, Budinger TF, Lebowitz E, Ansari AN, Greene MW, Fairchild RG. Thallium-201 for medical use. Part 3: human distribution and physical imaging properties. J Nucl Med 1984; 25: 1260-67.
5. Lebowitz E, Greene MW, Fairchild R et al. Thallium-201 for medical use. I. J Nucl Med 1975; 16: 151-5.
6. 99mTc Glucoheptonate as a brain imaging agent. Radiology 1979; 130: 421-3.
7. Nir I, Levanon D, Iosilevsky G. Permeability of blood vessels in experimental gliomas: uptake of 99mTc-glucoheptonate and alteration in blood-brain barrier as determined by cytochemistry and electron microscopy. Neurosurgery 1989; 25: 523-31.
8. Soricelli A, Cuocolo A, Varrone A et al. Technetium-99m-Tetrofosmin uptake in brain tumours by SPECT. Comparison with Thallium-201 imaging. J Nucl Med 1998; 39: 802-6.
9. O'Tuama LA, Packard AB, Treves ST. SPECT imaging of pediatric brain tumours with hexakis (methoxyisobutylisonitrile) technetium. J Nucl Med 1990; 31: 2040-41.
10. Staudenherz A, Fazeny B, Marosi C et al. Does (99m) Tc-sestamibi in high-grade malignant brain tumours reflect blood-brain barrier damage only? Neuroimage 2000; 12: 109-11.
11. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci NS 1978; 25: 638-43.
12. Barai S, Bandopadhayaya GP, Julka PK, Naik K, Haloi A, Malhotra A. Evaluation of tumour viability in post radiation therapy pediatric brain tumours with Tc-99m-glucoheptonate single photon emission computed tomography (SPECT). McGill J Med 2003; 7: 59-65.
13. De Kieviet W. Technetium radiopharmaceuticals: chemical characterization and tissue distribution of Tc-glucoheptonate using Tc-99m and carrier Tc-99. J Nucl Med 1981; 22: 703-9.
14. Lee HB, Blaufox MD. Mechanism of renal concentration of technetium-99m-glucoheptonate. J Nucl Med 1985; 26: 1308-13.
15. Levielle J, Pision C, Karakand Y et al. Technetium-99m glucoheptonate in brain tumour detection: an important advance in radiotracer technique. J Nucl Med 1977; 18: 957-61.
16. Tanasescu D, Wolfstein R, Waxman AD. Technetium-99m glucoheptonate as a brain scanning agent. J Nucl Med 1977; 18: 1037-8.
17. Kristiansen K, Hagen S, Kolleyvold T et al. Combined modality therapy of operated astrocytoma grade 3 and 4: confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicentre trial of the Scandanavian Glioblastoma Study Group. Cancer 1981; 47: 649-52.
18. Mahoney DH Jr, Strother D, Camitta B et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumours in children: a pilot pediatric oncology group study. J Clin Oncol 1996; 14: 382-8.
19. Hartmann M, Heiland S, Sartor K. Functional MRI procedures in the diagnosis of brain tumours. Perfusion- and diffusion-weighted imaging. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002; 174: 955-64.
20. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method to measure hemodynamics in brain tumours: validation and application of cerebral blood flow maps. AJNR 2000; 21: 462-70.
21. Nagamachi S, Jinnouchi S, Flores LG II et al. Evaluation of brain tumour by 99mTc-MIBI: comparison study with 201TI and predictivity of therapeutic effect. Kaku Igaku 1998; 35: 121-30.
22. Hirano T, Otake H, Kazama K et al. Technetium-99m (V)-DMSA and thallium-201 in brain tumour imaging: correlation with histology and malignant grade. J Nucl Med 1997; 38: 1741-9.
23. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumour from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96: 191-7.
24. Bae KT, Piwnica-Worms D. Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates. Q J Nucl Med 1997; 41: 101-10.